Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.

about

EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation.Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung Cancer

P2860

Q36155201-1D9D8446-1953-4634-B63F-EDDED293CA24 Q36192506-C22E6FA9-AD59-4DD3-B596-57D1BF8058A3

P2860

Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q38245669

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Moving from histological subty ...... ed non-small-cell lung cancer.

@en

type

Item

label

Moving from histological subty ...... ed non-small-cell lung cancer.

@en

prefLabel

Moving from histological subty ...... ed non-small-cell lung cancer.

@en

P1476

Moving from histological subty ...... ed non-small-cell lung cancer.

@en

P2093

Giorgio Vittorio Scagliotti

http://www.w3.org/2001/XMLSchema#string

Paolo Bironzo

http://www.w3.org/2001/XMLSchema#string

Silvia Novello

http://www.w3.org/2001/XMLSchema#string

Simona Carnio

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Characterizing the cancer genome in lung adenocarcinoma.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

P304

1495-1513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2014.949245

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25183305

http://www.w3.org/2001/XMLSchema#string

Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.

about

P2860

P2860

Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698